Gene Mutation Provides Resistance to HIV Infection
NEW YORK--Scientists at the Aaron Diamond AIDS Research Center appear to have solved one of the long-standing enigmas of HIV infection--why some people remain uninfected even after repeated exposures to the virus. The answer lies in the genes, and in basic research published only a few months earlier.
NEW YORK--Scientists at the Aaron Diamond AIDS Research Centerappear to have solved one of the long-standing enigmas of HIVinfection--why some people remain uninfected even after repeatedexposures to the virus. The answer lies in the genes, and in basicresearch published only a few months earlier.
Studies of two homosexual men who have avoided infection sincethe start of the AIDS epidemic, despite having HIV-positive partners,uncovered a genetic mutation that appears to protect against infectionwith the virus. Both men were found to have two mutant copiesof the CCR5 gene (also known as CKR-5, or chemokine receptor-5),whose discovery was reported by five different groups in Junein a flurry of papers in Nature, Science, and Cell.
The CCR5 gene produces a protein receptor that allows HIV entryinto human immune cells. The two men with the mutant gene didnot have the receptor, Dr. Nathan R. Landau and his colleaguesreported in the journal Cell (August 9, 1996).
Other work suggests that as many as 1% of whites of Western Europeandescent may have the gene mutation, and up to 20% of whites mayhave one copy of the defective gene. Even one copy may have aprotective role, either in lowering the risk of infection or indelaying progression of HIV after infection.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
